Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077619 | 0.93 | CNR1 (0.53) | CNR1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4079600 | 0.89 | CNR1 (0.53) | CNR1KMT2AALDH1A1CYP19A1MEN1 | |
| SCHEMBL4075806 | 0.85 | CNR1 (0.57) | CNR1ALDH1A1CYP19A1MAPTKDM4E | |
| SCHEMBL4085408 | 0.79 | CNR1 (0.57) | CNR1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4082543 | 0.78 | CNR1 (0.64) | CNR1ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL20154164 | 0.76 | ALDH1A1 (0.52) | KMT2AALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL4075638 | 0.74 | CNR1 (0.62) | CNR1SMN1; SMN2 | |
| SCHEMBL6553811 | 0.74 | CYP19A1 (0.47) | KMT2AALDH1A1CYP19A1MAPTSMN1; SMN2 | |
| SCHEMBL19864297 | 0.73 | ALDH1A1 (0.55) | KMT2AALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL19840110 | 0.73 | KMT2A (0.65) | KMT2AALDH1A1MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | claimed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | claimed |
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572785-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7057051-B2 | Substituted imidazoles as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2006-04-27 | — | — | US | disclosed |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | FONG TUNG M (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | MERCK SHARP & DOHME CORP. | 2003-06-19 | — | — | US | disclosed |
| WO-2003007887-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089356-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | CNR1 1/4885KMT2A 2183/4885ALDH1A1 3232/4885 |
| US-20030114495-A1 | Substituted imidazoles as cannabinoid receptor modulators | CNR1, CNR2, GPR119 | CNR1 1/4885KMT2A 2183/4885ALDH1A1 3232/4885 |
| US-20050171161-A1 | antagonizing Cannabinoid-1 (CB1) receptors and inhibiting the enzyme 11 beta -hydroxy steroid dehydrogenase-1 (11 beta -HSD1); appetite suppresion | CNR1, HSD11B1, HSD17B1 | CNR1 1/4885KMT2A 3110/4885ALDH1A1 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.